Nemvaleukin for Mucosal Melanoma Granted FDA’s Orphan Drug Status
Source: Targeted Oncology, March 2021
Nemvaleukin alfa (nemvaleukin; formerly ALKS 4230), an interleukin-2 (IL-2) variant immunotherapy for the treatment of mucosal melanoma, has been granted orphan drug designation by the FDA, according to a press release from developer Alkermes plc.1
